Analyst Christian Glennie from Stifel Nicolaus reiterated a Buy rating on Hikma Pharmaceuticals (HIK – Research Report) and keeping the ...

Shares of Hikma Pharmaceuticals PLC HIK rallied 1.64% to £18.01 Thursday, on what proved to be an all-around poor trading ...

London, United Kingdom – Hikma Pharmaceuticals PLC (Hikma ... business and are pleased to announce the signing of a significant new long-term contract with a global pharmaceutical company. Subject to ...

Hikma Pharmaceuticals (GB:HIK) has released an update. Hikma Pharmaceuticals has decided to reappoint PricewaterhouseCoopers LLP as its external auditor starting in 2026, following a competitive ...

Hikma Pharmaceuticals PLC HIK shares inched down 0.94% to £19.02 Wednesday, on what proved to be an all-around dismal trading ...

Hikma Pharmaceuticals will acquire parts of Danish firm Xellia Pharmaceuticals, a drug company specialising in injectable ...

The company also reiterated guidance for its Branded business of revenue in the high-single digits, or 6% to 8% higher year-on-year, with a core operating margin around 25%. Its Generics business is ...

Investing.com -- Shares of Hikma Pharmaceuticals (LON:HIK) jumped on Thursday after the company raised its full-year guidance ...

made by Hikma Pharmaceuticals, did not result in an increased survival rate compared with lower-dose versions of the drug when administered in emergency situations by New York law enforcement ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...